Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of this paper, the second graph in Figure 4B was erroneously identical with fourth graph in Figure 4B and correct version is provided below. We apologize for any inconvenience that may have been caused. The original article has been corrected as of 27th February 2025.

Original languageEnglish (US)
Pages (from-to)669-670
Number of pages2
JournalClinical and Molecular Hepatology
Volume31
Issue number2
DOIs
StatePublished - Apr 2025

ASJC Scopus subject areas

  • Hepatology
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]'. Together they form a unique fingerprint.

Cite this